ZNF165 As a Potential Novel Immunotherapeutic Target for Gastric Cancer

Fan Zhang,Kangmei Shao,Puyi He,Lin Xiang,Wenzhang Wu,Peng Zhang,Ewetse Paul Maswikiti,Yucai Wei,Furong Wang,Futian Tang,Duojie Zhu,Yumin Li

DOI: https://doi.org/10.21203/rs.3.rs-1942312/v1

2022-01-01

Abstract:Abstract Background: Cancer testis antigens (CTAs) are an extensive gene family with a unique expression pattern restricted to testis tissues, but aberrantly high expressed in a variety of cancer tissues. In view of this, CTAs are typically considered as efficient biomarkers and targets of immunotherapy. However, limited information is available regarding CTAs as immunotherapeutic targets for gastric cancer (GC) patients. Herein, we evaluated the expression levels of CTAs in both Eastern and Western GC patients and elucidate the expression pattern and functions of a novel CTAs. Method: Four independent GC and two human normal tissues retrospective cohorts were applied to detect expression patterns and clinical characteristics of CTAs. We identified the association between ZNF165 expression and tumor-infiltrated immune cells by using ESTIMATE, CIBERSORT algorithm and immunohistochemistry (IHC) staining. Functional enrichment analysis of ZNF165 were identified by using transcriptome sequencing. ZNF165 overexpression and knockdown in vitro and in vivo were used to assess the roles of ZNF165 in the cell cycle pathway. Results: ZNF165 expression significantly increased in GC tissues, especially in the intestinal type, MSI type, epithelial phenotype, and was associated with poor overall survival and disease-free survival for GC patients who received fluorouracil-based chemoradiation and radical gastrectomy. Little or no expression of ZNF165 was observed in human normal tissues, except for testis and placenta. Furthermore, ZNF165 was positively associated with pro-inflammatory tumor-infiltrating immune cells and tumor mutational burden (TMB). Enrichment analysis, in vivo and in vitro assays showed that ZNF165 could promote GC cell proliferation by regulating cell cycle. Conclusions: By demonstrating the expression pattern, clinical features, prognostic values and cellular functions of ZNF165 in GC, this study suggests that ZNF165 could serve as a potential novel immunotherapeutic target for GC patients.